AI Framework Helps Classify Renal Tumors, Predict Outcomes

Published Date: 07 Aug 2026

A deep learning system trained on whole-slide images classifies nine renal tumor subtypes with high accuracy and outperforms traditional grading in predicting patient outcomes.

Read Full News

Latest News

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Laser Therapy Shows Promise for Brain Tumors

Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.

Can Accelerated Salvage RT Improve Prostate Cancer Control?

After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.

Ibrutinib Fails in High-Risk Early-Stage CLL

Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.

Todays Updates

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Todays Updates

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Latest News

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.

After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.

Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.

News All Time

Belgian Algorithm Reshapes Endometrial Cancer Care

A new Belgian algorithm may help clinicians choose adjuvant therapy more precisely in early endometrial cancer, moving beyond TNM staging alone.

NPM1-Mutated AML: Not All Treatments Are Equal

Researchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.

Transgender Individuals Prefer HPV Self-Swabs

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

FDA Approves Iberdomide Combo for Multiple Myeloma

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

Wide Variation Seen in Lung Screening False-Positive Rates

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

How Low Does PSA Need to Go in Metastatic Prostate Cancer?

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

Do High-Risk Features of Prostate Cancer Boost HT Benefit?

Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.

AVD Chemo Regimen Shows Promise in Older Patients With HL

Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.

Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC

Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

Researchers compare enzalutamide vs abiraterone in the metastatic castration-sensitive prostate cancer setting.

Inconclusive BRCA Results Linked to Higher BC Risk

A new study assesses breast and ovarian cancer risk in women who carry a BRCA variant of uncertain significance or have a noninformative negative result.

OA Tied to Arthritis AE Risk in ICI-Treated Patients

In patients with cancer receiving immune checkpoint inhibitor therapy, osteoarthritis is linked to the risk for inflammatory arthritis immune-related adverse events.

Stem Cell Transplant Linked to Longer Survival in CMML

Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Recommended News For You

Appropriate New Monoclonal for Immunocompromised Individuals to Prevent COVID-19.

Prostate cancer therapies: AI-based image analysis detects early organ damage

Headlines About Doc Who 'Catches' Patient's Cancer Are Popping Up Again

According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.

Cancer during young adulthood carries long-term mental toll, study finds

Some low-grade prostate cancers carry higher risks than biopsy suggests

Resection for Early Liver Cancer Tied to Improved Survival.

Recommended Articles For You

Survival Rates in Cancer: Focus on Acute Myeloid Leukemia and Other Malignancies 

Unlocking the Benefits of Eltrombopag: A Comprehensive Guide 

The Lung Cancer Shift: From Reactive Treatment to Proactive Precision Medicine 

Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

We Don't Always Know What's 'Best' for Our Patients

2.

FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.

3.

DBT Reduced Suicide Attempts in Adolescents with Bipolar Disorder.

4.

Axatilimab Demonstrates Effectiveness in Refractory/Recurrent GVHD.

5.

AI Framework Helps Classify Renal Tumors, Predict Outcomes

1.

The Genetics of Bernard Soulier Syndrome: What We Know so Far

2.

The New Frontier of Cancer Survivorship: Navigating the Long-Term Effects of Immunotherapy and Targeted Therapies

3.

Exploring the Mystery of Angiokeratomas on Scrotum: Causes, Symptoms and Treatment

4.

IGF2BP1 in Blood Disorders: Therapeutic Potential and Comprehensive Functional Insights

5.

Survivorship Care Planning Beyond Active Cancer Treatment: Advancing Care Continuity for Cancer Survivors

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI

2.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

3.

Preventing Blood Clots: The Importance of Venous Thromboembolism Management

4.

Innovations in Hematology

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot